>>> US Gapping up

Gapping up
In reaction to earnings/guidance:

  • UPWK +26.4%, REZI +18.9%, QCOM +14.5%, CPRI +13.2%, ODP +9.3%, WCC +9%, MTW +8.2%, WK +8%, QLYS +7.7%, CCRN +7.1%, MELI +6.6%, PRGO +6.6%, AG +6.3%, CRON +6.3%, COMM +6.2%, OBSV +5.9%, NXST +5.8%, GM +5.8%, LUMN +5.7%, ET +5.6%, CRY +5.5%, LCUT +5.5%, VG +5.4%, SRCL +4.9%, DCP +4.8%, VSTO +4.8%, EXPE +4.5%, FOE +4.3%, MDP +4.3%, IIVI +4.2%, PH +4.2%, MTCH +4.1%, LSPD +4.1%, GDDY +4%, CMRX +3.9%, KGC +3.8%, ALB +3.7%, CAH +3.7%, AWK +3.6%, NS +3.6%, HOLX +3.4%, PDCE +3.4%, AAON +3.3%, GOLD +3.2%, LNTH +3.2%, YETI +3.1%, PRMW +3.1%, THS +3.1%, BDX +3%, ALL +2.9%, PLUS +2.9%, IRM +2.9%, SJI +2.8%, KL +2.7%, GPX +2.6%, SPNS +2.6%, TYL +2.5%, RPD +2.4%, CEIX +2.4%, TSLX +2.3%, JKHY +2.3%, PSTG +2.2%, LNC +2.2%, LC +2.2%, AMRN +2.2%, QRVO +2.1%, MT +2.1%, UHAL +2%, TWO +2%, APA +2%, IAG +2%, PODD +1.9%, LHCG +1.9%, AZN +1.9%, PAAS +1.8%, SAGE +1.8%, GOOS +1.8%, ANSS +1.7%, PZZA +1.7%, BMY +1.7%, SRE +1.7%, STWD +1.6%, QGEN +1.5%, FNV +1.5%, LBTYA +1.5%, SHYF +1.5%, CXW +1.4%

Other news:

  • APHA +13.7% (to acquire SweetWater Brewing)
  • MGNX +10.5% (files for $100 mln mixed securities shelf offering)
  • JCS +8% (acquired the operating assets of privately held IVDesk)
  • GMAB +5.2% (Genmab confirms that Janssen (JNJ) submitted Type II variation application to the European Medicines Agency for use of subcutaneous DARZALEX (daratumumab) in patients with light-chain amyloidosis; triggers a USD 5 million milestone payment to Genmab)
  • BDSI +4% (new CEO; also authorizes new $25 mln share repurchase program)
  • LMPX +3.2% (announces exclusive new vehicle lease/subscription agreement with LTO Holdings)
  • ENDP +2.5% (announces strategic actions to optimize operations)
  • VRTX +2% (receives EC approval for KALYDECO; Approval provides opportunity to treat the underlying cause of cystic fibrosis earlier than ever before in Europe)
  • COST +1.7% (reports October total comps +14.4%)
  • MRK +1.5% (to acquire VelosBio for $2.75 billion in cash)
  • GILD +1.4% (ProteoNic licenses its 2G UNic technology platform for production of biologics to Gilead)

Analyst comments:

  • LOGI +4.5% (upgraded to Buy from Hold at Kepler)
  • CLH +3.3% (upgraded to Buy from Neutral at UBS)
  • CS +2.7% (upgraded to Buy from Hold at Kepler)
  • MSFT +2.7% (upgraded to Outperform from Perform at Oppenheimer)
  • WU +2.7% (upgraded to Neutral from Sell at Citigroup)
  • PYPL +2.6% (upgraded to Buy from Hold at DZ Bank)
  • VZ +1.3% (upgraded to Overweight from Neutral at JP Morgan)